A possible contribution of altered cathepsin b expression to the development of skin sclerosis and vasculopathy in systemic sclerosis

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Noda, Shinji ^a   Asano, Yoshihide ^a   Akamata, Kaname ^a   Aozasa, Naohiko ^a   Taniguchi, Takashi ^a   Takahashi, Takehiro ^a   Ichimura, Yohei ^a   Toyama, Tetsuo ^a   Sumida, Hayakazu ^a   Yanaba, Koichi ^a   Tada, Yayoi ^a   Sugaya, Makoto ^a   Kadono, Takafumi ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CATHEPSIN B; TRANSCRIPTION FACTOR FLI 1; TRANSFORMING GROWTH FACTOR BETA1; CTSB PROTEIN, HUMAN; CTSB PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIMITED CUTANEOUS SYSTEMIC SCLEROSIS; MAJOR CLINICAL STUDY; MALE; MICROVASCULAR ENDOTHELIAL CELL; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; SKIN NECROSIS; SKIN ULCER; SYSTEMIC SCLEROSIS; VASCULAR DISEASE; WILD TYPE; ANIMAL; BIOSYNTHESIS; CASE CONTROL STUDY; CYTOLOGY; EXTRACELLULAR MATRIX; METABOLISM; METHODOLOGY; MICROCIRCULATION; PATHOLOGY; PHYSIOLOGY; SKIN;

MUS;

ANIMALS; CASE-CONTROL STUDIES; CATHEPSIN B; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GENE SILENCING; HUMANS; MALE; MICE; MICROCIRCULATION; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA; VASCULAR DISEASES;

EID: 84863126451     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032272     Document Type: Article

References (42)

1. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202-205.
2. Distler J, Gay S, Distler O, (2006) Angiogenesis and vasculogenesis in systemic sclerosis. Rheumatology (Oxford) 45 (Suppl 3): iii26-27.
3. Manetti M, Guiducci S, Ibba-Manneschi L, Matucci-Cerinic M, (2010) Mechanisms in the loss of capillaries in systemic sclerosis: angiogenesis versus vasculogenesis. J Cell Mol Med 14: 1241-1254.
4. Reiser J, Adair B, Reinheckel T, (2010) Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 120: 3421-3431.
5. Obermajer N, Jevnikar Z, Doljak B, Kos J, (2008) Role of cysteine cathepsins in matrix degradation and cell signalling. Connect Tissue Res 49: 193-196.
6. Moles A, Tarrats N, Fernández-Checa JC, Marí M, (2009) Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 49: 1297-1307.
7. Chang SH, Kanasaki K, Gocheva V, Blum G, Harper J, et al. (2009) VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res 69: 4537-4544.
8. Malla RR, Gopinath S, Gondi CS, Alapati K, Dinh DH, et al. (2011) Cathepsin B and uPAR knockdown inhibits tumor-induced angiogenesis by modulating VEGF expression in glioma. Cancer Gene Ther 18: 419-434.
9. Im E, Venkatakrishnan A, Kazlauskas A, (2005) Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol Biol Cell 16: 3488-3500.
10. Dziankowska-Bartkowiak B, Waszczykowska E, Zalewska A, Sysa-Jedrzejowska A, (2005) Correlation of endostatin and tissue inhibitor of metalloproteinases 2 (TIMP2) serum levels with cardiovascular involvement in systemic sclerosis patients. Mediators Inflamm 2005: 144-149.
11. Dziankowska-Bartkowiak B, Waszczykowska E, Dziankowska-Zaboroszczyk E, de Graft-Johnson JE, Zalewska A, et al. (2006) Decreased ratio of circulatory vascular endothelial growth factor to endostatin in patients with systemic sclerosis-association with pulmonary involvement. Clin Exp Rheumatol 24: 508-513.
12. Distler O, Del Rosso A, Giacomelli R, Cipriani P, Conforti M, et al. (2002) Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Res 4: R11.
13. Hummers LK, Hall A, Wigley FM, Simons M, (2009) Abnormalities in the regulators of angiogenesis in patients with scleroderma. J Rheumatol 36: 576-582.
14. Hebbar M, Peyrat JP, Hornez L, Hatron PY, Hachulla E, et al. (2000) Increased concentrations of the circulating angiogenesis inhibitor endostatin in patients with systemic sclerosis. Arthritis Rheum 43: 889-893.
15. LeRoy E, Black C, Fleischmajer R, Jablonska S, Krieg T, et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202-205.
16. No authors listed (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 23: 581-590.
17. Steen VD, Powell DL, Medsger TA, (1988) Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31: 196-203.
18. Sato S, Ihn H, Kikuchi K, Takehara K, (1994) Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. Arthritis Rheum 37: 391-394.
19. Noda S, Asano Y, Aozasa N, Akamata K, Yamada D, et al. (2011) Serum Tie2 levels: clinical association with microangiopathies in patients with systemic sclerosis. J Eur Acad Dermatol Venereol.
20. Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, et al. (1993) Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 20: 1892-1896.
21. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K, (2004) Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts. J Clin Invest 113: 253-264.
22. Asano Y, Stawski L, Hant F, Highland K, Silver R, et al. (2010) Endothelial Fli1 deficiency impairs vascular homeostasis: a role in scleroderma vasculopathy. Am J Pathol 176: 1983-1998.
23. Asano Y, Trojanowska M, (2009) Phosphorylation of Fli1 at threonine 312 by protein kinase C delta promotes its interaction with p300/CREB-binding protein-associated factor and subsequent acetylation in response to transforming growth factor beta. Mol Cell Biol 29: 1882-1894.
24. Hervé-Grépinet V, Veillard F, Godat E, Heuzé-Vourc'h N, Lecaille F, et al. (2008) Extracellular catalase activity protects cysteine cathepsins from inactivation by hydrogen peroxide. FEBS Lett 582: 1307-1312.
25. Bujor AM, Asano Y, Haines P, Lafyatis R, Trojanowska M, (2011) The c-Abl tyrosine kinase controls protein kinase Cδ-induced Fli-1 phosphorylation in human dermal fibroblasts. Arthritis Rheum 63: 1729-1737.
26. Akada H, Yan D, Zou H, Fiering S, Hutchison RE, et al. (2010) Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease. Blood 115: 3589-3597.
27. Spyropoulos DD, Pharr PN, Lavenburg KR, Jackers P, Papas TS, et al. (2000) Hemorrhage, impaired hematopoiesis, and lethality in mouse embryos carrying a targeted disruption of the Fli1 transcription factor. Mol Cell Biol 20: 5643-5652.
28. Kuroda K, Shinkai H, (1997) Gene expression of types I and III collagen, decorin, matrix metalloproteinases and tissue inhibitors of metalloproteinases in skin fibroblasts from patients with systemic sclerosis. Arch Dermatol Res 289: 567-572.
29. LeRoy EC, (1996) Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 22: 675-694.
30. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S.
31. Rhew EY, Barr WG, (2004) Scleroderma renal crisis: new insights and developments. Curr Rheumatol Rep 6: 129-136.
32. Abraham DJ, Krieg T, Distler J, Distler O, (2009) Overview of pathogenesis of systemic sclerosis. Rheumatology (Oxford) 48 (Suppl 3): iii3-7.
33. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, et al. (2005) Increased expression of integrin alpha(v)beta3 contributes to the establishment of autocrine TGF-beta signaling in scleroderma fibroblasts. J Immunol 175: 7708-7718.
34. Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, et al. (2005) Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 52: 2897-2905.
35. Asano Y, Ihn H, Yamane K, Jinnin M, Tamaki K, (2006) Increased expression of integrin alphavbeta5 induces the myofibroblastic differentiation of dermal fibroblasts. Am J Pathol 168: 499-510.
36. Dziadzio M, Smith RE, Abraham DJ, Black CM, Denton CP, (2005) Circulating levels of active transforming growth factor beta1 are reduced in diffuse cutaneous systemic sclerosis and correlate inversely with the modified Rodnan skin score. Rheumatology (Oxford) 44: 1518-1524.
37. Kubo M, Czuwara-Ladykowska J, Moussa O, Markiewicz M, Smith E, et al. (2003) Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol 163: 571-581.
38. Miami Winter Synposium website. Available: http://www.med.miami.edu/mnbws/documents/06Yamasaki.pdf. Accessed 2005 Dec 14.
39. Ram M, Sherer Y, Shoenfeld Y, (2006) Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 26: 299-307.
40. Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, et al. (2008) Capillary regeneration in scleroderma: stem cell therapy reverses phenotype? PLoS One 3: e1452.
41. Hoyland JA, Newson L, Jayson MI, Freemont AJ, (1993) The vascular basement membrane in systemic sclerosis skin: heterogeneity of type IV collagen. Br J Dermatol 129: 384-388.
42. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaissé J, (2000) Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 486: 247-251.